Matches in Wikidata for { <http://www.wikidata.org/entity/Q66397983> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- Q66397983 description "clinical trial" @default.
- Q66397983 description "ensayu clínicu" @default.
- Q66397983 description "klinisch onderzoek" @default.
- Q66397983 description "клінічне випробування" @default.
- Q66397983 name "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis" @default.
- Q66397983 name "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis" @default.
- Q66397983 type Item @default.
- Q66397983 label "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis" @default.
- Q66397983 label "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis" @default.
- Q66397983 prefLabel "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis" @default.
- Q66397983 prefLabel "Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis" @default.
- Q66397983 P1050 Q66397983-DD7C3A6D-6393-42C8-9967-AFA05D8632D8 @default.
- Q66397983 P1132 Q66397983-79102935-A985-446F-8900-2667392D43D1 @default.
- Q66397983 P1476 Q66397983-93DC1A94-4BF5-4FC4-AE3F-0E3240B8D025 @default.
- Q66397983 P17 Q66397983-16F93BA8-963C-4810-A549-27A7662DC664 @default.
- Q66397983 P17 Q66397983-1B85B0CF-8B98-4BAB-9964-6BA4B39FDCB3 @default.
- Q66397983 P17 Q66397983-1CE62C0C-35A9-4588-94FD-A453CC3028A7 @default.
- Q66397983 P17 Q66397983-301DA9BE-D359-4879-ADDD-0B7AD33BCC05 @default.
- Q66397983 P17 Q66397983-32970818-DBAC-45F6-B94A-B4D09987A17E @default.
- Q66397983 P17 Q66397983-594A2D63-B0F1-451C-864E-785B12F6559C @default.
- Q66397983 P17 Q66397983-632A0D02-1F9E-4C93-A2CC-313AEB6CA08C @default.
- Q66397983 P17 Q66397983-63A4F747-0837-4FFE-AEAF-AAF1E164215C @default.
- Q66397983 P17 Q66397983-8613FAC0-49B0-40DE-9831-0848FDDDD216 @default.
- Q66397983 P17 Q66397983-89932817-4D38-41D9-9BFB-0C24DB9D3D37 @default.
- Q66397983 P17 Q66397983-D77768D0-D638-4BAD-845C-5C29E8BD5249 @default.
- Q66397983 P17 Q66397983-DEC153EE-2D25-4DEC-8B59-351B8A54F5B0 @default.
- Q66397983 P17 Q66397983-FCBBF05D-207D-4BFF-AAF6-7F178B3BB44A @default.
- Q66397983 P2899 Q66397983-DB459BFE-204E-4D4E-AD56-DEAE4649B56D @default.
- Q66397983 P3098 Q66397983-38C80070-E6A0-42AB-A813-1C1DEE11381E @default.
- Q66397983 P31 Q66397983-965FB054-D566-4829-A5FF-370A449F5D99 @default.
- Q66397983 P580 Q66397983-DFF044B4-3CA5-4706-98FD-931B95900DF1 @default.
- Q66397983 P582 Q66397983-B7B25008-A277-4EC3-B865-2ED73F0E75F0 @default.
- Q66397983 P6099 Q66397983-490BDFFA-3558-4806-B7AF-4C3E5575024A @default.
- Q66397983 P8363 Q66397983-D9C270DA-C92B-4CD6-8544-C54FD2DDF234 @default.
- Q66397983 P1050 Q170990 @default.
- Q66397983 P1132 "+695" @default.
- Q66397983 P1476 "A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION" @default.
- Q66397983 P17 Q145 @default.
- Q66397983 P17 Q183 @default.
- Q66397983 P17 Q214 @default.
- Q66397983 P17 Q219 @default.
- Q66397983 P17 Q258 @default.
- Q66397983 P17 Q28 @default.
- Q66397983 P17 Q29 @default.
- Q66397983 P17 Q30 @default.
- Q66397983 P17 Q31 @default.
- Q66397983 P17 Q36 @default.
- Q66397983 P17 Q408 @default.
- Q66397983 P17 Q928 @default.
- Q66397983 P17 Q96 @default.
- Q66397983 P2899 "+18" @default.
- Q66397983 P3098 "NCT02831855" @default.
- Q66397983 P31 Q30612 @default.
- Q66397983 P580 "2016-09-01T00:00:00Z" @default.
- Q66397983 P582 "2018-11-19T00:00:00Z" @default.
- Q66397983 P6099 Q42825046 @default.
- Q66397983 P8363 Q78089383 @default.